Dendritic Cell-Based Immunotherapies and their Potential use in Colorectal Cancer Immunotherapy

Alia M Aldahlawi; Samaa Taha Abdullah

doi:10.4103/jmau.jmau_20_21

Dendritic Cell-Based Immunotherapies and their Potential use in Colorectal Cancer Immunotherapy

J Microsc Ultrastruct. 2021 Jul 9;10(3):107-113. doi: 10.4103/jmau.jmau_20_21. eCollection 2022 Jul-Sep.

Authors

Alia M Aldahlawi^{1

2}, Samaa Taha Abdullah¹

Affiliations

¹ Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
² Immunology Unit, King Fahad Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.

Abstract

Dendritic cells (DCs) are professional antigen-presenting cells, which are resident or proliferating in organs. Major histocompatibility complex (MHC) Class I and II on DCs in normal steady conditions process and present antigens including cancer antigens. Many approaches are used to enhance antigen presentation process of DCs and capture cancer cells. DCs are harvested from cancer patients and manipulated ex vivo in DC-based cancer immunotherapy. In addition, DCs' vaccines and other anticancer therapy combinations were discussed to optimize DCs' efficiency for cancer immunotherapy. This review addressed the use of the human conventional type-1 DCs, OX40⁺ plasmacytoid DCs, and DCs-derived exosomes. In addition, different combinations with DCs therapy such as combination with the monoclonal antibody, cytokine-induced killer cells, adjuvants, chemotherapy (DCs-based chemoimmunotherapy), and nanoparticles were listed and explored for their effectiveness against cancer, and mainly against colorectal cancer.

Keywords: Adjuvants; OX40+ plasmacytoid dendritic cells; colorectal cancer; cytokine-induced killer cells; dendritic cells; dendritic cells-based chemoimmunotherapy; exosomes; nanoparticles-dendritic cells immunotherapy.

Publication types

Review